In a significant procedural development in the Northern District of California, Judge Edward J. Davila sua sponte ordered the consolidation of two parallel patent infringement actions — ChromaCode, Inc. v. Bio-Rad Laboratories, Inc., Case No. 5:23-cv-04823-EJD and Case No. 5:23-cv-06360-EJD — into a single consolidated proceeding styled In re ChromaCode Litigation. Filed in December 2023 and consolidated on August 16, 2024, the disputes center on patents covering digital PCR technology, with Bio-Rad’s QX600 Droplet Digital PCR System at the heart of the controversy. The three patents-in-suit — US11827921B2, US10068051B2, and US10770170B2 — reflect core innovations in multiplexed nucleic acid analysis.

This consolidation carries strategic weight for IP professionals navigating the rapidly evolving digital PCR and molecular diagnostics space. The court’s order signals that overlapping claim construction disputes across related PCR patents will be resolved in a unified proceeding, concentrating litigation risk and precedent-setting power in a single docket. Biotechnology patent holders, licensees, and competitors in the PCR instrumentation market should closely monitor In re ChromaCode Litigation as it advances through the Northern District of California.

Case Overview

The Parties

The Patents at Issue

The three patents-in-suit — US11827921B2, US10068051B2, and US10770170B2 — cover innovations in digital polymerase chain reaction (PCR) technology, specifically methods and systems for performing highly multiplexed nucleic acid detection and quantification. These patents protect techniques enabling simultaneous detection of multiple genetic targets within droplet-partitioned reaction systems, which are foundational to products like Bio-Rad’s QX600 Droplet Digital PCR System. Their claims are central to next-generation molecular diagnostics, oncology research, and infectious disease testing platforms.

• • US11827921B2
• • US10068051B2
• • US10770170B2

Legal Representation

Plaintiff Counsel: Sheppard Mullin Richter & Hampton LLP; Wilson Sonsini Goodrich & Rosati, PC (lead: Amy H. Candido)
Defendant Counsel: Weil Gotshal & Manages, LLP (lead: Cole Uzat)

Litigation Timeline & Procedural History

Case No. 5:23-cv-06360 was filed on December 11, 2023 in the United States District Court for the Northern District of California, San Jose Division — a venue with well-established expertise in complex technology patent disputes and frequently selected for life science and biotechnology IP litigation. This case represents a first-instance district court proceeding, meaning it was filed at the trial court level with no prior appellate history, and was subject to the court’s standard patent case management scheduling order.

The case ran for 249 days before closure on August 16, 2024, a relatively swift resolution attributable not to a merits determination but to procedural consolidation. Rather than proceeding to claim construction, summary judgment, or trial, the court sua sponte ordered consolidation with the related ChromaCode #1 action (5:23-cv-04823-EJD) under Federal Rule of Civil Procedure 42(a), citing common questions of law and fact, overlapping patent claims, and substantially similar case management schedules. The termination basis — case consolidation — means no damages, no injunction, and no validity determination has yet been reached; all substantive proceedings now continue under the master docket In re ChromaCode Litigation.

The Verdict & Legal Analysis

Outcome

The court did not reach the merits of the infringement or invalidity claims in Case No. 5:23-cv-06360. Instead, on August 16, 2024, Judge Davila issued an Order of Consolidation under Fed. R. Civ. P. 42(a), terminating this docket and transferring all proceedings, filings, and attorney appearances into the consolidated master action, In re ChromaCode Litigation, Case No. 5:23-cv-04823-EJD. No damages were awarded, no injunctive relief was granted, and no claim construction rulings were issued in this case — those determinations remain pending in the consolidated proceeding.

Verdict Cause Analysis

The court’s consolidation order rested on several well-established legal principles governing case management in complex patent disputes:

• Both ChromaCode #1 and ChromaCode #2 involved the same plaintiff (ChromaCode, Inc.) and defendant (Bio-Rad Laboratories, Inc.), satisfying the threshold requirement of overlapping parties under Rule 42(a).
• The court found that both actions arose from related PCR technology and would require construction and interpretation of the same patents, creating common questions of law and fact that strongly favored consolidation.
• The Ninth Circuit’s broad discretion standard for consolidation — as articulated in Investors Research Co. v. U.S. Dist. Ct., 877 F.2d 777 (9th Cir. 1989) — supported judicial economy as the primary rationale, with no identified risk of delay, confusion, or prejudice.
• The substantially similar case management schedules of both actions eliminated any prejudice concern that might otherwise counsel against consolidation, making the procedural alignment of the two dockets a material factor in the court’s decision.

Legal Significance

1. 1. The court’s sua sponte consolidation under Rule 42(a) — without a formal motion by either party — underscores the Northern District of California’s active case management posture in complex multi-docket patent disputes involving overlapping technologies and claim construction questions.
2. 2. The consolidation means that claim construction rulings issued in In re ChromaCode Litigation will simultaneously govern infringement claims by ChromaCode and invalidity defenses raised by Bio-Rad, creating a single high-stakes Markman hearing with outcome-determinative implications for both PCR patent portfolios.
3. 3. For pending or future PCR patent disputes in the Northern District, this case signals that plaintiffs filing successive related actions face a meaningful risk of judicial consolidation, potentially limiting their ability to sequence litigation strategy across separate dockets.

Strategic Takeaways

For Patent Attorneys:

• When filing successive related patent actions against the same defendant in the same district, counsel should anticipate and prepare for sua sponte consolidation orders — particularly where overlapping claim construction is foreseeable.
• The consolidated proceeding will require coordinated claim construction briefing across patents US11827921B2, US10068051B2, and US10770170B2 simultaneously; early alignment of claim term prioritization across all asserted patents is essential.
• Bio-Rad’s dual posture — as both a defendant on infringement and an asserter of invalidity — creates a complex Markman landscape; attorneys should map how proposed claim constructions in one posture may undermine the other.
• The admission of all counsel from the terminated 5:23-cv-06360 docket into the consolidated master action without re-filing streamlines appearances but requires immediate attention to updated scheduling orders and deadlines in the master case.

For IP Professionals:

• In-house IP teams in the digital PCR and molecular diagnostics space should monitor In re ChromaCode Litigation (5:23-cv-04823-EJD) as a single consolidated proceeding that will yield claim construction rulings with broad implications for the scope of multiplexed digital PCR patent protection.
• The involvement of both ChromaCode and the California Institute of Technology as co-plaintiffs signals a university-industry patent enforcement partnership; competitors should audit their product portfolios against Caltech’s broader PCR-related patent estate as a precautionary measure.

For R&D Teams:

• Engineering and product teams developing droplet digital PCR systems or multiplexed nucleic acid detection platforms should conduct freedom-to-operate analysis against US11827921B2, US10068051B2, and US10770170B2 before advancing hardware or assay designs toward commercialization.
• The QX600 Droplet Digital PCR System’s centrality to this dispute indicates that instrument-level digital PCR architectures are under active patent scrutiny; R&D leaders should document design choices and explore alternative partitioning or multiplexing architectures as potential design-around pathways.